Nuo Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nuo Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $721.0K | Apr 16, 2018 |
| FY2017 | Dec 31, 2016 | $472.4K | Apr 16, 2018 |
| FY2015 | Dec 31, 2015 | $11.51M | Oct 24, 2016 |
| FY2015 | Dec 31, 2014 | $7.76M | Oct 24, 2016 |
| FY2013 | Dec 31, 2013 | $11.57M | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $10.56M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $7.25M | Mar 18, 2013 |
| FY2011 | Dec 31, 2010 | $3.91M | Mar 29, 2012 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2014 | $7.76M | Mar 31, 2015 |
| FY2014 | Dec 31, 2013 | $11.57M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $7.24M | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $5.90M | Mar 18, 2013 |
| FY2011 | Dec 31, 2010 | $3.79M | Mar 29, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.22M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.06M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $482.4K | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $93.0K | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Apr 17, 2023 |
| FY2021 | Sep 30, 2021 | $0 | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | $0 | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | $0 | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Apr 15, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.51M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($2.32M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($3.17M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($3.17M) | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | ($90.7K) | Apr 17, 2023 |
| FY2021 | Sep 30, 2021 | ($6.8K) | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | ($6.5K) | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | ($5.7K) | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | ($90.9K) | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | ($15.5K) | Apr 15, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.52M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($2.46M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($3.17M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($3.32M) | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | ($90.7K) | Apr 17, 2023 |
| FY2021 | Sep 30, 2021 | ($6.8K) | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | ($6.5K) | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | ($5.7K) | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | ($378.1K) | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | ($6.3K) | Apr 15, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Apr 15, 2022 |
| FY2021 | Sep 30, 2021 | $0 | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | $0 | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | $0 | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $0 | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Apr 15, 2022 |
| FY2021 | Jun 30, 2020 | $0 | Apr 15, 2022 |
| FY2021 | Mar 31, 2020 | $0 | Apr 15, 2022 |
| FY2021 | Dec 31, 2019 | $181.2K | Apr 15, 2022 |
| FY2018 | Dec 31, 2018 | $576.2K | Apr 16, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.73M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $3.52M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $3.65M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $3.41M | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $90.7K | Apr 17, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($865.0K) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($2.23M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($3.17M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($3.71M) | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | ($120.0K) | Apr 17, 2023 |
| FY2021 | Sep 30, 2021 | ($13.0K) | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | ($9.8K) | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | ($4.2K) | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | ($53.8K) | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | ($20.3K) | Apr 15, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $274.8K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $155.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.2K | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $60.0K | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Apr 17, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Apr 15, 2022 |
| FY2021 | Dec 31, 2019 | $0 | Apr 15, 2022 |
| FY2015 | Dec 31, 2015 | $698.2K | Oct 24, 2016 |
| FY2015 | Dec 31, 2014 | $483.0K | Oct 24, 2016 |
| FY2014 | Dec 31, 2013 | $750.7K | Mar 31, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.85M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.19M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.88M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $3.05M | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $1.47M | Apr 17, 2023 |
| FY2021 | Sep 30, 2021 | $149.9K | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | $153.1K | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | $157.3K | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $161.4K | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | $0 | Apr 15, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.80M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $675.8K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $838.7K | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $856.0K | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | $673.1K | Apr 17, 2023 |
| FY2021 | Sep 30, 2021 | $672.5K | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | $668.9K | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | $666.5K | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | $665.0K | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | $1.03M | Apr 15, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($956.6K) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $513.7K | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $1.04M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $2.19M | Apr 1, 2025 |
| FY2023 | Dec 31, 2021 | $792.8K | Apr 19, 2024 |
| FY2021 | Sep 30, 2021 | ($522.5K) | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | ($515.8K) | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | ($509.2K) | Apr 15, 2022 |
| FY2022 | Dec 31, 2020 | ($503.5K) | Apr 17, 2023 |
| FY2021 | Sep 30, 2020 | ($1.03M) | Apr 15, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2017 | $0 | Apr 16, 2019 |
| FY2018 | Jun 30, 2017 | $0 | Apr 16, 2019 |
| FY2018 | Dec 31, 2016 | $2.08M | Apr 16, 2019 |
| FY2017 | May 5, 2016 | $2.10M | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 29, 2017 |
| FY2016 | Sep 30, 2015 | $0 | Mar 29, 2017 |
| FY2016 | Dec 31, 2014 | $0 | Mar 29, 2017 |
| FY2014 | Dec 31, 2013 | $1.13M | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $1.13M | Mar 31, 2014 |
| FY2013 | Dec 31, 2011 | $706.8K | Mar 31, 2014 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.77M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($32.26M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($29.94M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($26.76M) | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | ($23.59M) | Apr 17, 2023 |
| FY2021 | Sep 30, 2021 | ($23.52M) | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | ($23.51M) | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | ($23.51M) | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | ($23.50M) | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | ($23.27M) | Apr 15, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $548.9K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $283.7K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $928.7K | Apr 1, 2025 |
| FY2024 | Dec 31, 2022 | $2.05M | Apr 1, 2025 |
| FY2023 | Dec 31, 2021 | $1.41M | Apr 19, 2024 |
| FY2021 | Sep 30, 2021 | $148.4K | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | $151.6K | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | $157.3K | Apr 15, 2022 |
| FY2022 | Dec 31, 2020 | $161.4K | Apr 17, 2023 |
| FY2021 | Sep 30, 2020 | $0 | Apr 15, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Apr 15, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 17, 2023 |
| FY2021 | Sep 30, 2021 | 0 | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Apr 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | 0 | Apr 15, 2022 |
| FY2021 | Jun 30, 2020 | 0 | Apr 15, 2022 |
| FY2021 | Mar 31, 2020 | 0 | Apr 15, 2022 |
| FY2021 | Dec 31, 2019 | 0 | Apr 15, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Apr 16, 2019 |
| FY2018 | Dec 31, 2017 | (1) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 16, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 48.18M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 46.82M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 44.24M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 41.80M | Apr 19, 2024 |
| FY2022 | Dec 31, 2021 | 37.12M | Apr 17, 2023 |
| FY2021 | Sep 30, 2021 | 30.26M | Apr 15, 2022 |
| FY2021 | Jun 30, 2021 | 30.26M | Apr 15, 2022 |
| FY2021 | Mar 31, 2021 | 30.26M | Apr 15, 2022 |
| FY2021 | Dec 31, 2020 | 30.26M | Apr 15, 2022 |
| FY2021 | Sep 30, 2020 | 24.25M | Apr 15, 2022 |